Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Mild to Moderate Alzheimer's Disease
KCT0001134Phase 3
Key facts
- Status
- Recruiting
- Start
- Jan 2014
- Countries
- 1
- Sponsor
- Worldwide Clinical Trials
- Modality
- Small Molecules
- Conditions
- Alzheimer's disease (AD)
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing LMTM with Placebo (2 arms). Started Jan 2014; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
LMTM
Participants receive leuco-methylthioninium bis(hydromethanesulfonate) for 12 months.
Placebo
Participants receive matching placebo for 12 months.
03
Who it enrols
Adults with mild to moderate Alzheimer's disease in Korea; healthy volunteers are not included.
Beyond the preview
Go deeper on KCT0001134.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001134.